Sign in
BCYC Stock Price, Chart, Stats & News
Bicycle Therapeutics plc
Save
281.05M
Market cap
–
Current P/E
–
Forward P/E
BCYC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -125.05% |
Operating margin | -340.31% |
Pretax margin | -301.45% |
Net margin | -301.66% |
Effective tax rate | -0.07% |
ROA | -30.51% |
ROE | -33.20% |
D/E | 0.03x |
Interest coverage ratio | -1199.58x |
BCYC valuation
P/E | – |
P/S | 4.11x |
P/B | 0.49x |
P/CF | -1.20x |
P/FCF | -1.20x |
P/OCF | -1.20x |
PEG | -0.11x |
EV multiple | -3.88x |
About
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials.
Similar securities
Based on sector and market capitalization
Report issue